Source: Citybizlist

ReViral: Pfizer Acquires ReViral

NEW YORK-(BUSINESS WIRE)-Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical... Read MoreThe post Pfizer Acquires ReViral appeared first on citybiz.

Read full article »

ReViral's Competitors | ReViral's News | ReViral's Financials

Followers on Owler

Est. Annual Revenue

$25-100M

Est. Employees

25-100

CEO

Alex C. Sapir

CEO Approval Rating

84/100

Reviral is an England-based biopharmaceutical company that develops and commercializes antiviral therapeutics for the treatment of the respiratory syncytial virus.